Showing 2871-2880 of 5771 results for "".
- Seonix Bio Launches SightScore, the First Clinical Polygenic Risk Score Test for Glaucoma in the UShttps://modernod.com/news/seonix-bio-launches-sightscore-the-first-clinical-polygenic-risk-score-test-for-glaucoma-in-the-us/2482672/Seonix Bio announced the US launch of SightScore, which the company descibes as the first commercially available clinical polygenic risk score testing service for primary open-angle glaucoma. Already available in Australia and New Zealand, SightScore utilizes
- Opthea Treats Final Patient in Phase 3 COAST Trial for Wet AMDhttps://modernod.com/news/opthea-treats-final-patient-in-phase-3-coast-trial-for-wet-amd/2482668/Opthea announced that it has completed the final week 52 patient visit in COAST, the first of two phase 3 pivotal trials investigating the superiority and safety of sozinibercept in combination with aflibercept (COAST) or ranibizumab (ShORe), compared to standard of care alone for the treatm
- Fred Moll, Founder of Intuitive Surgical, Joins ForSight Robotics Board of Directorshttps://modernod.com/news/fred-moll-founder-of-intuitive-surgical-joins-forsight-robotics-board-of-directors/2482664/ForSight Robotics announced that Fred Moll, MD, the founder of Intuitive Surgical, has joined its Board of Directors. Intuitive Surgical is the company behind the da Vinci surgical system, the first robotic surgical platform commercially available in the US 
- Virtual Vision Health Launches Visual Acuity Testing on Virtual Eye VR Platformhttps://modernod.com/news/virtual-vision-health-launches-visual-acuity-testing-on-virtual-eye-vr-platform/2482663/Virtual Vision Health announced the launch of visual acuity testing on its Virtual Eye VR platform. According to Virtual Vision, with patients needing regular visual acuity testing to monitor changes and maintain overall eye health, this feature ensures prov
- AAO Responds to Proposed Cuts to NIH Research Paymentshttps://modernod.com/news/aao-responds-to-proposed-cuts-to-nih-research-payments/2482660/The National Institutes of Health (NIH) announced Friday that it is cutting grants that support research and academic institutions by limiting the amount of indirect funding for research projects to just 15%. Currently, the average indirect costs rate for organizations receiving NIH grants is bet
- TECLens Secures $9.3 Million Series A Funding to Advance Its Noninvasive Refractive Technologyhttps://modernod.com/news/teclens-secures-93-million-series-a-funding-to-advance-its-noninvasive-refractive-technology/2482658/TECLens announced it raised $9.3 million in a Series A round to support the clinical development of the company’s non-incisional refractive correction procedure that leverages corneal cross-linking (CXL) to reshape the cornea. The funding round was co-led by Johnson &
- DigitalOptometrics to Preview 'World’s First Autonomous Slitlamp' at Vision Expo East 2025https://modernod.com/news/digitaloptometrics-to-preview-worlds-first-autonomous-slitlamp-at-vision-expo-east-2025/2482655/DigitalOptometrics has announced the launch of what it is calling the world’s first and most advanced autonomous slitlamp with remote control capabilities at Vision Expo East (VEE) 2025 in Orlando. In collaboration with SlitLED, DigitalOptometrics will demonstrate t
- 4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Studyhttps://modernod.com/news/4dmt-presents-positive-52-week-results-from-phase-2b-cohort-of-prism-wet-amd-study/2482654/4D Molecular Therapeutics (4DMT) announced positive initial interim 52-week data from the phase 2b population extension cohort of the PRISM clinical trial evaluating 4D-150 in a broad wet age-related macular degeneration (AMD) patient population. Additional data were provided on the durabili
- Bausch + Lomb: No Immediate Plans to Go Privatehttps://modernod.com/news/bausch-lomb-no-immediate-plans-to-go-private/2482653/After exploring options to separate from Bausch Health, Bausch + Lomb announced Thursday it decided not to engage in a sale. “Taking Bausch + Lomb private with a third-party buyer was one of several options being explored to complete a full separation from Bausch Health Companies
- Lumenis Launches OptiLIFT, Device to Address Lower Lid Laxity and Impaired Blinkinghttps://modernod.com/news/lumenis-launces-optilift-device-to-address-lower-lid-laxity-and-impaired-blinking/2482652/Lumenis announced the launch of OptiLIFT, a new device that uses Dynamic Muscle Stimulation technology (DMSt) to tone facial muscles to improve lower lid laxity and impaired blinking. OptiLIFT marks one of the first treatment options that eliminates the need for surgery. “Op